{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T17:16:51Z","timestamp":1773681411054,"version":"3.50.1"},"reference-count":39,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2004,6,1]],"date-time":"2004-06-01T00:00:00Z","timestamp":1086048000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2004,6]]},"DOI":"10.1016\/j.lungcan.2003.12.001","type":"journal-article","created":{"date-parts":[[2004,3,23]],"date-time":"2004-03-23T18:29:08Z","timestamp":1080066548000},"page":"355-362","source":"Crossref","is-referenced-by-count":16,"title":["Phase II study of carboplatin and weekly paclitaxel combination chemotherapy in advanced non-small cell lung cancer: a Kansai Clinical Oncology Group study"],"prefix":"10.1016","volume":"44","author":[{"given":"Masataka","family":"Hirabayashi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuo","family":"Endoh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masayoshi","family":"Teramachi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masato","family":"Okuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuyuki","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kohji","family":"Fukuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidetoshi","family":"Tokuhisa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hitoshi","family":"Kagioka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoharu","family":"Nakai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaharu","family":"Nakade","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2003.12.001_BIB1","doi-asserted-by":"crossref","first-page":"3210","DOI":"10.1200\/JCO.2001.19.13.3210","article-title":"Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial","volume":"19","author":"Kelly","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2003.12.001_BIB2","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1056\/NEJMoa011954","article-title":"Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer","volume":"346","author":"Schiller","year":"2002","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.lungcan.2003.12.001_BIB3","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1038\/bjc.1993.488","article-title":"Cytotoxic studies of paclitaxel in human tumor cell lines","volume":"68","author":"Liebmann","year":"1993","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.lungcan.2003.12.001_BIB4","first-page":"449","article-title":"Paclitaxel cytotoxicity against human lung cancer cell lines increases with prolonged exposure durations","volume":"3","author":"Georgiadis","year":"1997","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2003.12.001_BIB5","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1200\/JCO.1994.12.8.1621","article-title":"Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: a phase I\/II trial of 96-hour infusion","volume":"12","author":"Wilson","year":"1994","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2003.12.001_BIB6","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1200\/JCO.1996.14.6.1877","article-title":"Ninety-six-hour paclitaxel infusion after progression during short taxane exposure: a phase II pharmacokinetic and pharmacodynamic study in metastatic breast cancer","volume":"14","author":"Seidman","year":"1996","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2003.12.001_BIB7","unstructured":"Gilewski T, Norton L. Cytokinetics and breast cancer chemotherapy. In: Harris JR, Lippman ME, Morrow M, et al., editors. Diseases of the breast. Philadelphia, PA: Lippincott\/Raven, 1996. p. 1877\u201384."},{"key":"10.1016\/j.lungcan.2003.12.001_BIB8","first-page":"816","article-title":"Mitotic block in Hela cells by low concentrations of paclitaxel resilts in abnormal mitotic exit and apoptotic cell death","volume":"56","author":"Jordan","year":"1996","journal-title":"Cancer Res."},{"issue":"Suppl. 14","key":"10.1016\/j.lungcan.2003.12.001_BIB9","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1053\/sonc.2001.27607","article-title":"Weekly paclitaxel in advanced non-small cell lung cancer","volume":"28","author":"Chang","year":"2001","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.lungcan.2003.12.001_BIB10","doi-asserted-by":"crossref","first-page":"3353","DOI":"10.1200\/JCO.1998.16.10.3353","article-title":"Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer","volume":"16","author":"Seidman","year":"1998","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2003.12.001_BIB11","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1200\/JCO.1997.15.1.187","article-title":"Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer","volume":"15","author":"Fennelly","year":"1997","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2003.12.001_BIB12","doi-asserted-by":"crossref","first-page":"767","DOI":"10.2482\/haigan.41.767","article-title":"Dose finding study of carboplatin and weekly paclitaxel for advanced non-small cell lung cancer","volume":"41","author":"Hirabayashi","year":"2001","journal-title":"Jpn. J. Cancer"},{"key":"10.1016\/j.lungcan.2003.12.001_BIB13","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1023\/A:1008207025430","article-title":"Short-course intravenous prophylaxis for paclitaxel-related hypersensitivity reactions","volume":"8","author":"Bookman","year":"1997","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2003.12.001_BIB14","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/0959-8049(95)00641-9","article-title":"Phase I study with a weekly 1 hour infusion of paclitaxel in heavily pretreated patients with metastatic breast and ovarian cancer","volume":"32A","author":"Klaasen","year":"1996","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.lungcan.2003.12.001_BIB15","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1200\/JCO.1989.7.11.1748","article-title":"Carboplatin dosage: prospective evaluation of a simple formula based on renal function","volume":"7","author":"Calvert","year":"1989","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2003.12.001_BIB16","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-79-4-604","article-title":"Letter: creatinine clearance: bedside estimate","volume":"79","author":"Jelliffe","year":"1973","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.lungcan.2003.12.001_BIB17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","article-title":"Optimal two-stage designs for phase II clinical trials","volume":"10","author":"Simon","year":"1989","journal-title":"Contr. Clin. Trials"},{"key":"10.1016\/j.lungcan.2003.12.001_BIB18","unstructured":"World Health Organization. The WHO handbook for reporting results of cancer treatment. Geneva: World Health Organization, 1979."},{"key":"10.1016\/j.lungcan.2003.12.001_BIB19","doi-asserted-by":"crossref","first-page":"457","DOI":"10.2307\/2281868","article-title":"Non-parametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J. Am. Stat. Assoc."},{"key":"10.1016\/j.lungcan.2003.12.001_BIB20","first-page":"35a","article-title":"Weekly paclitaxel followed by FAC as primary systemic chemotherapy of operable breast cancer improves pathologic complete remission rates when compared to every 3-week paclitaxel therapy followed by FAC\u2014final results of a prospective phase III randomized trial [abstract]","volume":"21","author":"Green","year":"2002","journal-title":"Proc. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2003.12.001_BIB21","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1200\/JCO.2001.19.10.2587","article-title":"Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification","volume":"19","author":"Seidman","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2003.12.001_BIB22","first-page":"380a","article-title":"An updated analysis of a randomized study of single agent paclitaxel given weekly versus every 3 weeks to patients with ovarian cancer treated with prior platinum therapy [abstract]","volume":"19","author":"Andersson","year":"2000","journal-title":"Proc. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2003.12.001_BIB23","first-page":"3942","article-title":"A phase II study of weekly paclitaxel in elderly patients with advanced non-small cell lung cancer","volume":"7","author":"Fidias","year":"2001","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2003.12.001_BIB24","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/S0169-5002(01)00441-X","article-title":"Is weekly paclitaxel superior to paclitaxel given every 3 weeks? Results of a phase II trial","volume":"35","author":"Koumakis","year":"2002","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2003.12.001_BIB25","first-page":"271b","article-title":"Low-dose weekly paclitaxel in the treatment of unresectable or metastatic non-small cell lung cancer. Neurological and electrophysiological evaluation of neurotoxicity [abstract]","volume":"20","author":"Vidal","year":"2001","journal-title":"Proc. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2003.12.001_BIB26","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1002\/cncr.10835","article-title":"Second-line, low-dose, weekly paclitaxel in patients with stage IIIB\/IV nonsmall cell ling carcinoma who fail first-line chemotherapy with carboplatin plus paclitaxel","volume":"95","author":"Socinski","year":"2002","journal-title":"Cancer"},{"key":"10.1016\/j.lungcan.2003.12.001_BIB27","first-page":"462a","article-title":"CALGB9731: phase II trial of weekly paclitaxel for advanced non-small cell lung cancer [abstract]","volume":"18","author":"Akerley","year":"1999","journal-title":"Proc. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2003.12.001_BIB28","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s11912-001-0017-4","article-title":"Recent developments in weekly paclitaxel therapy in lung cancer","volume":"3","author":"Akerley","year":"2001","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.lungcan.2003.12.001_BIB29","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1200\/JCO.2000.18.1.122","article-title":"Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer","volume":"18","author":"Sandler","year":"2000","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2003.12.001_BIB30","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1200\/JCO.1998.16.7.2459","article-title":"Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer. A Southwest Oncology Group study","volume":"16","author":"Wozniak","year":"1998","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2003.12.001_BIB31","first-page":"1a","article-title":"Single-agent versus combination chemotherapy in advanced non-small cell lung cancer: a CALGB randomized trial of efficacy, quality of life, and cost-effectiveness [abstract]","volume":"21","author":"Lilenbaum","year":"2002","journal-title":"Proc. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2003.12.001_BIB32","first-page":"291a","article-title":"Gemcitabine compared with gemcitabine plus carboplatin in advanced non-small cell lung cancer: a phase III study by the Swedish Lung Cancer Study Group [abstract]","volume":"21","author":"Sederholm","year":"2002","journal-title":"Proc. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2003.12.001_BIB33","first-page":"291a","article-title":"Preliminary analysis of a multicenter phase III trial comparing docetaxel versus docetaxel\/cisplatin in patients with inoperable advanced and metastatic non-small cell lung cancer [abstract]","volume":"21","author":"Georgoulias","year":"2002","journal-title":"Proc. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2003.12.001_BIB34","first-page":"421","article-title":"Phase II trial of carboplatin in non-small cell lung cancer","volume":"70","author":"Olver","year":"1986","journal-title":"Cancer Treat. Rep."},{"key":"10.1016\/j.lungcan.2003.12.001_BIB35","doi-asserted-by":"crossref","first-page":"3857","DOI":"10.1200\/JCO.2002.08.129","article-title":"Phase II multicenter trial of a weekly paclitaxel and carboplatin regimen in patients with advanced breast cancer","volume":"20","author":"Loesch","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2003.12.001_BIB36","doi-asserted-by":"crossref","first-page":"4285","DOI":"10.1200\/JCO.2002.02.068","article-title":"Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer","volume":"20","author":"Scagliotti","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2003.12.001_BIB37","first-page":"1087","article-title":"New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions","volume":"5","author":"Bunn","year":"1998","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2003.12.001_BIB38","first-page":"323a","article-title":"Phase II multicenter randomized trial of weekly paclitaxel administered in combination with carboplatin followed by maintenance paclitaxel vs observation for patients with advanced & metastatic non-small cell lung cancer [abstract]","volume":"20","author":"Belani","year":"2001","journal-title":"Proc. Am. Soc. Clin. Oncol."},{"issue":"Suppl. 14","key":"10.1016\/j.lungcan.2003.12.001_BIB39","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/S0093-7754(01)90054-5","article-title":"Interim analysis of a phase II study of induction weekly paclitaxel\/carboplatin regimens followed by maintenance weekly paclitaxel for advanced and metastatic non-small cell lung cancer","volume":"28","author":"Belani","year":"2001","journal-title":"Semin. Oncol."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500203006275?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500203006275?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,2,14]],"date-time":"2019-02-14T12:56:21Z","timestamp":1550148981000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500203006275"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,6]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2004,6]]}},"alternative-id":["S0169500203006275"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2003.12.001","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2004,6]]}}}